Comparing Single Versus Multiple Anti-VEGF Injections in Diabetic Patients Undergoing Cataract Surgery

Summary

Objective of this randomised controlled trial is to compare the efficacy of a single per operative anti VEGF injection with repeated postoperative anti VEGF injections in the prevention of diabetic retinopathy progression after cataract surgery. This Randomised Controlled Trial (RCT) will be conducted at Sahiwal Teaching Hospital and University College of Medicine \& Dentistry Lahore. Duration of study will be from January 2026 to September 2026. This study will be single blind and parallel group research. The study will include diabetic patients of both sexes ≥ 40 years of age presenting with non-proliferative diabetic retinopathy and cataract. Exclusion criteria include proliferative diabetic retinopathy, center-involving diabetic macular oedema (DME), poor glycemic control (HbA1c \>9%), glaucoma, uveitis, prior ocular surgery or laser, and recent systemic thromboembolic events. Subjects will be randomly divided into two groups, each containing 83 subjects. Standard phacoemulsification with intraocular lens implantation will be performed in all participants. A single intra vitreal Aflibercept injection ( 2mg/0.05 ml ), will be given to group 1 participants. While, group 2 participants will receive an intra operative injection plus two additional injections at 1 month and 2 months postoperatively. For all participants, follow up will be performed at 1 week, 1 month, 2 month, 3 month and 6 month. Primary Outcome include progression of diabetic retinopathy (DR) severity (≥1 stage according to the guidelines of the international clinical diabetic retinopathy disease severity scale ICDR) or onset/progression of DME. Secondary Outcomes include changes in best corrected visual acuity, changes in central macular thickness (CMT), and need for rescue treatment. SPSS version 26 will be utilised to analyse the data. P ≤ 0.05 will be taken as statistically significant. Qualitative variable like diabetic retinopathy grading and diabetic macular oedema status will be analysed by utilising Pearson's chi-square test. Quantitative variables like central macular thickness will be analysed by employing t-test.

Timeline

Start

2026-01-01

Primary completion

2026-06-30

Completion

2026-09-30

Publications

• Background Wilkinson CP, Ferris FL 3rd, Klein RE, Lee PP, Agardh CD, Davis M, Dills D, Kampik A, Pararajasegaram R, Verdaguer JT; Global Diabetic Retinopathy Project Group. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology. 2003 Sep;110(9):1677-82. doi: 10.1016/S0161-6420(03)00475-5.
• Background Pollack A, Dotan S, Oliver M. Progression of diabetic retinopathy after cataract extraction. Br J Ophthalmol. 1991 Sep;75(9):547-51. doi: 10.1136/bjo.75.9.547.
• Background Chung J, Kim MY, Kim HS, Yoo JS, Lee YC. Effect of cataract surgery on the progression of diabetic retinopathy. J Cataract Refract Surg. 2002 Apr;28(4):626-30. doi: 10.1016/s0886-3350(01)01142-7.
• Background Starr MR, Mahr MA, Smith WM, Iezzi R, Barkmeier AJ, Bakri SJ. Outcomes of Patients With Active Diabetic Macular Edema at the Time of Cataract Surgery Managed With Intravitreal Anti-Vascular Endothelial Growth Factor Injections. Am J Ophthalmol. 2021 Sep;229:194-199. doi: 10.1016/j.ajo.2021.04.002. Epub 2021 Apr 20.
• Background Hu W, Ni L, Ying H, Zhang Z, Tu S, Tao Y, Chen L. Efficacy of fluocinolone acetonide implant in diabetic macular edema patients previously treated with dexamethasone implant: A systematic review and meta-analysis. Pak J Med Sci. 2025 Aug;41(8):2388-2398. doi: 10.12669/pjms.41.8.12675.
• Background Cheema RA, Al-Mubarak MM, Amin YM, Cheema MA. Role of combined cataract surgery and intravitreal bevacizumab injection in preventing progression of diabetic retinopathy: prospective randomized study. J Cataract Refract Surg. 2009 Jan;35(1):18-25. doi: 10.1016/j.jcrs.2008.09.019.
• Background Haddad JE, Sabbakh NA, Macaron MM, Shaaban H, Bourdakos NE, Shi A, Saad B, Nakanishi H, Than CA, Daoud YJ. NSAIDs and Corticosteroids for the Postoperative Management of Age-Related Cataract Surgery: A Systematic Review and Meta-analysis. Am J Ophthalmol. 2024 Apr;260:1-13. doi: 10.1016/j.ajo.2023.09.027. Epub 2023 Oct 4.
• Background Kropp M, Golubnitschaja O, Mazurakova A, Koklesova L, Sargheini N, Vo TKS, de Clerck E, Polivka J Jr, Potuznik P, Polivka J, Stetkarova I, Kubatka P, Thumann G. Diabetic retinopathy as the leading cause of blindness and early predictor of cascading complications-risks and mitigation. EPMA J. 2023 Feb 13;14(1):21-42. doi: 10.1007/s13167-023-00314-8. eCollection 2023 Mar.
• Background Kaur A, Kumar R, Sharma A. Diabetic Retinopathy Leading to Blindness- A Review. Curr Diabetes Rev. 2024;20(9):e240124225997. doi: 10.2174/0115733998274599231109034741.
• Background Han X, Zhang J, Liu Z, Tan X, Jin G, He M, Luo L, Liu Y. Real-world visual outcomes of cataract surgery based on population-based studies: a systematic review. Br J Ophthalmol. 2023 Aug;107(8):1056-1065. doi: 10.1136/bjophthalmol-2021-320997. Epub 2022 Apr 11.
• Background Lee SH, Tseng BY, Wu MC, Wang JH, Chiu CJ. Incidence and Progression of Diabetic Retinopathy After Cataract Surgery: A Systematic Review and Meta-Analysis. Am J Ophthalmol. 2025 Jan;269:105-115. doi: 10.1016/j.ajo.2024.08.017. Epub 2024 Aug 22.
• Background Rachmilevich A, Yanculovich N, Hazan I, Tsumi E, Liberty IF. Glycemic control and macular edema in patients undergoing cataract surgery. Prim Care Diabetes. 2023 Feb;17(1):55-59. doi: 10.1016/j.pcd.2022.12.004. Epub 2023 Jan 2.
• Background Sruthi R, Saikumar SJ, Gopalakrishnan M. Progression of diabetic retinopathy following uncomplicated phacoemulsification: A prospective study from South India. Oman J Ophthalmol. 2024 Feb 21;17(1):72-77. doi: 10.4103/ojo.ojo_292_22. eCollection 2024 Jan-Apr.
• Background Wu J, Zhou Y, Zhen F, Wang S, Li Q, Dong S. Management after cataract surgery for patients with diabetic retinopathy: a systematic review and meta-analysis. Int Ophthalmol. 2024 Apr 1;44(1):166. doi: 10.1007/s10792-024-02981-6.

Drugs

Indications